Klotho Neurosciences, Inc. (KLTO)
Klotho Neurosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Omaha, NE, US. The stock last traded at $0.38, down 7.10% on the session, giving a market capitalisation of $20.1M. On trailing twelve-month figures it carries a trailing P/E of -1.13, a net margin of 0.0%. Its beta of 2.23 implies it has historically moved more than the broad market.
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska.
Klotho Neurosciences, Inc. is most often compared with the following Healthcare names: